PL3909584T3 - Związek pirymidynowy lub jego sól - Google Patents

Związek pirymidynowy lub jego sól

Info

Publication number
PL3909584T3
PL3909584T3 PL20737875.3T PL20737875T PL3909584T3 PL 3909584 T3 PL3909584 T3 PL 3909584T3 PL 20737875 T PL20737875 T PL 20737875T PL 3909584 T3 PL3909584 T3 PL 3909584T3
Authority
PL
Poland
Prior art keywords
salt
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
PL20737875.3T
Other languages
English (en)
Inventor
Masayuki Nakamura
Takahiro Asai
Satoru Iguchi
Kei OGUCHI
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3909584T3 publication Critical patent/PL3909584T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL20737875.3T 2019-01-11 2020-01-10 Związek pirymidynowy lub jego sól PL3909584T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019003403 2019-01-11
PCT/JP2020/000592 WO2020145374A1 (ja) 2019-01-11 2020-01-10 ピリミジン化合物又はその塩

Publications (1)

Publication Number Publication Date
PL3909584T3 true PL3909584T3 (pl) 2024-03-25

Family

ID=71520288

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20737875.3T PL3909584T3 (pl) 2019-01-11 2020-01-10 Związek pirymidynowy lub jego sól

Country Status (20)

Country Link
US (1) US11078207B2 (pl)
EP (1) EP3909584B1 (pl)
JP (1) JP6783974B1 (pl)
KR (1) KR102640463B1 (pl)
CN (1) CN113271950B (pl)
AU (1) AU2020206640B2 (pl)
CA (1) CA3121722C (pl)
DK (1) DK3909584T5 (pl)
ES (1) ES2969151T3 (pl)
FI (1) FI3909584T3 (pl)
HU (1) HUE065967T2 (pl)
MA (1) MA54702A (pl)
MX (1) MX2021008252A (pl)
MY (1) MY206124A (pl)
PH (1) PH12021551630A1 (pl)
PL (1) PL3909584T3 (pl)
PT (1) PT3909584T (pl)
SG (1) SG11202107528PA (pl)
TW (1) TWI783204B (pl)
WO (1) WO2020145374A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
US12492208B2 (en) 2020-07-15 2025-12-09 Taiho Pharmaceutical Co., Ltd. Crystal of pyrimidine compound
KR102873219B1 (ko) * 2020-07-15 2025-10-17 다이호야쿠힌고교 가부시키가이샤 Egfr 저해제
CA3199714A1 (en) * 2020-11-20 2022-05-27 Isao Miyazaki Brain-migrating tumor therapeutic agent containing fused pyrimidine compound as active ingredient
AU2022282261A1 (en) * 2021-05-24 2023-12-21 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2
WO2024173565A2 (en) * 2023-02-14 2024-08-22 New York University Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
MX360498B (es) * 2013-08-12 2018-11-05 Taiho Pharmaceutical Co Ltd Compuesto novedoso de pirimidina fusionada o sal del mismo.
KR102075886B1 (ko) 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
DK3269370T3 (da) 2016-02-23 2020-04-06 Taiho Pharmaceutical Co Ltd Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf
SG11201809223PA (en) 2016-04-19 2018-11-29 Univ California Erbb inhibitors and uses thereof
JP6779835B2 (ja) 2017-06-15 2020-11-04 株式会社日立製作所 監視制御システム、監視制御装置及び監視制御方法

Also Published As

Publication number Publication date
ES2969151T3 (es) 2024-05-16
EP3909584A1 (en) 2021-11-17
TWI783204B (zh) 2022-11-11
CN113271950B (zh) 2024-04-30
US11078207B2 (en) 2021-08-03
EP3909584A4 (en) 2022-09-28
EP3909584B1 (en) 2023-12-13
DK3909584T5 (da) 2024-08-05
MY206124A (en) 2024-11-30
CN113271950A (zh) 2021-08-17
TW202043230A (zh) 2020-12-01
KR102640463B1 (ko) 2024-02-23
MA54702A (fr) 2021-11-17
KR20210102373A (ko) 2021-08-19
WO2020145374A1 (ja) 2020-07-16
DK3909584T3 (da) 2024-01-15
US20210024530A1 (en) 2021-01-28
AU2020206640B2 (en) 2022-09-08
AU2020206640A1 (en) 2021-08-12
PT3909584T (pt) 2024-01-12
SG11202107528PA (en) 2021-08-30
PH12021551630A1 (en) 2022-06-06
FI3909584T3 (fi) 2024-01-09
CA3121722A1 (en) 2020-07-16
JPWO2020145374A1 (ja) 2021-02-18
CA3121722C (en) 2024-01-16
MX2021008252A (es) 2021-08-16
BR112021013460A2 (pt) 2021-09-21
JP6783974B1 (ja) 2020-11-11
HUE065967T2 (hu) 2024-07-28

Similar Documents

Publication Publication Date Title
ZA201905332B (en) Novel condensed pyrimidine compound or salt thereof
ZA202207543B (en) Pyridazinyl-thiazolecarboxamide compound
IL257306B (en) A compressed pyrimidine compound or a salt thereof
SG11201801365YA (en) NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
HUE065967T2 (hu) Pirimidin-vegyület vagy annak sója
PL3827042T3 (pl) Związek wielo-azyrydynowy
IL274037A (en) A pyrimidine compound as a JAK kinase inhibitor
GB202011800D0 (en) Compound
IL290692A (en) Salt
PT3466934T (pt) Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
ZA202100765B (en) Crystalline epinephrine malonate salt
IL281391A (en) An imidazopyridinone compound
IL290345A (en) Pyrimidine-5-carboxamide compounds
PT3630729T (pt) Composto de pirimidina
GB202110403D0 (en) Ulodesine Salt
IL281765A (en) Aminopyrimidine compound
GB201809460D0 (en) Salt form
GB201809458D0 (en) Salt form
HUE060733T2 (hu) Pirrolo[2,3-d]pirimidin vegyület vagy annak sója
GB201904190D0 (en) Salt
GB202104272D0 (en) Salt
HK40075942A (en) Salt
GB202004504D0 (en) Salt
HK40025121A (zh) 嘧啶化合物
GB201908466D0 (en) Compound